Skip to main content
SSO 2026 Annual Meeting Main banner

P71. Secreted methionine adenosyltransferase α2: a potential target in the development of colorectal liver metastases

Thursday, March 5, 2026
3:07 PM - 3:14 PM MST
Location: 101A-C
Introduction: Colorectal liver metastasis (CRLM) occurs in 50% of patients with colorectal cancer (CRC). Methionine adenosyltransferase (MAT) catalyzes the formation of S-adenosylmethionine (SAMe), the principal methyl donor. MAT1A (encodes MATα1) is expressed in normal adult liver, whereas MAT2A (encodes MATα2) is expressed in all extrahepatic tissues. MAT1A is a major defense against CRLM as loss of Mat1a sensitizes the liver to CRLM. In contrast, MAT2A is overexpressed in CRC and promotes oncogenicity. We found that human hepatocytes co-cultured with RKO (human CRC) cells, had lower MAT1A expression. We sought to determine if MATα2 is secreted by CRC and if it affects hepatocytes’ MAT1A expression.


Methods:

Our study included human hepatocytes, RKO cells, extracellular vesicle (EV) isolation, chromatin immunoprecipitation (ChIP), ChIP-seq, promoter activity assays, proliferation, migration, and invasion assays, western blotting, immunohistochemistry and immunofluorescence. We confirmed some of the findings using human hepatocyte spheroids, CRLM and normal liver tissue array, and plasma samples.


Results:

CRCs secrete MATα2 in free but truncated form (MATα2-t) and intact within EVs. EV-MATα2 can be internalized by human hepatocytes and found within the nucleus, which then binds to MAT1A and MAT2A promoters on ChIP to lower and increase MAT1A and MAT2A promoter activities, respectively. In human CRLM samples, hepatocytes in nontumor regions express lower MATα1 but higher MATα2 as compared to normal liver. Treating RKO cells with EVs released from RKO cells overexpressing MAT2A promoted cell proliferation, migration, and invasion. MATα2-t was detected at a higher level in media from colon, pancreatic, and prostate cancer cell lines than corresponding normal epithelial cells as well as CRC patients’ plasma than healthy controls. RKO cells treated with MATα2-t activated focal adhesion kinase (FAK), an important kinase for cancer cell evasion of apoptosis. Conversely, treatment with MATα2 neutralizing antibody inhibited FAK and induced apoptosis.


Conclusions: CRC cells secrete both MATα2 within EVs and free MATα2-t. EV-MATα2 can be internalized and act as a transcription factor to lower hepatocytes’ MAT1A, the major defense against CRLM, while promoting CRC oncogenicity. Freely released MATα2-t acts as a ligand in an autocrine fashion to activate FAK, which is essential for CRC survival. Taken together, secreted MATα2 plays an essential role in promoting CRLM. Furthermore, MATα2-t is a potential novel therapeutic target.

Learning Objectives:

  • Explain how colorectal cancer cells secrete MATα2 in both extracellular vesicles (EVs) and truncated free forms, and how these influence hepatocyte gene expression.
  • Discuss the mechanism by which EV-mediated MATα2 alters hepatocyte MAT1A and MAT2A promoter activity, contributing to a microenvironment favorable for colorectal liver metastasis.
  • Recognize the autocrine role of truncated MATα2 in activating focal adhesion kinase (FAK) signaling for colorectal cancer survival and the potential of targeting secreted MATα2 to prevent or treat CRLM